WILLIAM A. BRIGGS, M.D.; RICHARD J. ROZEK, M.S.; STEPHEN D. MIGDAL, M.D.; JOAN L. SHILLIS, Ph.D.; ROBERT G. BRACKETT, Ph.D.; FRANK B. BRANDON, Ph.D.; SUDESH K. MAHAJAN, M.D.; FRANKLIN D. McDONALD, M.D.
Influenza infection in renal transplant recipients may cause either morbidity and mortality or acute allograft rejection; thus, routine annual influenza vaccination should be considered. We have studied the humoral and cellular immune responses to influenza virus antigens before and after trivalent vaccine administration in 13 patients and 16 control subjects. The patients, nine of whom were either on alternate-day or low-dose daily steroid therapy, showed highly significant serum hemagglutination-inhibition antibody responses to each influenza virus strain. There was no significant change in mean lymphocyte stimulation index to any influenza virus strain after vaccination in either group. There was no correlation in the patient group between hemagglutination-inhibition antibody titer or response, or lymphocyte stimulation index or response, and the degree of allograft function or dose or duration of immunosuppressive therapy. The vigorous antibody response and the evidence of cellular immunity support the efficacy of influenza vaccination in these patients.
BRIGGS WA, ROZEK RJ, MIGDAL SD, SHILLIS JL, BRACKETT RG, BRANDON FB, et al. Influenza Vaccination in Kidney Transplant Recipients: Cellular and Humoral Immune Responses. Ann Intern Med. 1980;92:471–477. doi: 10.7326/0003-4819-92-4-471
Download citation file:
Published: Ann Intern Med. 1980;92(4):471-477.
Infectious Disease, Influenza, Nephrology, Prevention/Screening, Renal Replacement Therapy.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use